Name | Abemaciclib | CAS# | 1231929-97-7 | |
---|---|---|---|---|
Price | ¥Inquiry/1g | Purity | 98.9% | |
Stocking Period |
1 Day | Stock | In Stock |
Detail
Product Information
LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. |
Get all suppliers by the below link:
2024-07-15 |
Abemaciclib
Price: Inquiry |
2019-03-05 |
Abemaciclib
Price: ¥2578.0 |
2020-01-06 |
LY2835219 free base (Abemaciclib)
Price: $250.0 |
2021-07-26 |
N-[5-[(4-Ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamine
Price: $Inquiry |
2025-09-17 |
Abemaciclib
Price: ¥Inquiry |
2024-01-09 |
N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine
Price: $Inquiry |
2023-11-02 |
Abemaciclib
Price: ¥Inquiry |
2017-12-15 |
Abemaciclib
Price: ¥Inquiry |
2017-06-10 |
Abemaciclib (LY2835219)
Price: ¥Inquiry |
Get all price from the following link:
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved